Litigation Details for Cephalon Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Cephalon Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Docket	1:13-cv-02095	Date Filed	2013-12-26
Court	District Court, D. Delaware	Date Terminated	2016-08-23
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,436,190; 8,445,524; 8,609,863
Link to Docket	External link to docket

Details for Cephalon Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-26				External link to document

Litigation Summary and Analysis for Cephalon Inc. v. Accord Healthcare Inc. | 1:13-cv-02095

Last updated: January 9, 2026

Executive Summary

This case involves Cephalon Inc., a pharmaceutical innovator specializing in neurology and oncology therapies, suing Accord Healthcare Inc., a generic drug manufacturer, for patent infringement concerning a branded pharmaceutical product. Initiated in 2013, the dispute encapsulates key issues over patent validity, infringement, and the scope of patent protection for complex biologic-like drugs. This analysis synthesizes the litigation timeline, claims, defenses, judicial reasoning, and implications for generic drug entry strategies and patent protection standards.

---

What Are the Background and Context of the Case?

Clinical and Commercial Context

Cephalon's blockbuster drug, Provigil® (modafinil), is indicated for narcolepsy, shift work sleep disorder, and excessive daytime sleepiness. It secured multiple patents protecting its formulation, method of use, and manufacturing processes, prolonging market exclusivity.

Accord Healthcare sought to develop a generic version following patent expiration or challenge. The case centered on whether Accord’s proposed product infringed Cephalon’s patents and whether those patents were valid.

Key Patent Holders and the Technology

• Cephalon’s patent portfolio primarily included U.S. Patent No. 7,479,491 and U.S. Patent No. 8,147,307.
• The patents claimed methods of making modafinil, specific formulations with extended-release properties, and particular dosage regimens.

---

What Are the Main Legal Claims and Defenses?

Cephalon's Claims	Accord's Defenses
Patent infringement of the '491 and '307 patents	Non-infringement by designing around claims
Patent validity of the asserted patents	Patent invalidity due to anticipation or obviousness
Damages for ongoing sales of infringing drugs	Challenging patent enforceability and scope
Injunctive relief to prevent sales	Invalidity and non-infringement defenses

---

What Was the Litigation Timeline and Procedural Posture?

Date	Event	Detail
April 16, 2013	Complaint filed	Cephalon alleges patent infringement by Accord Healthcare.
August 2013	No preliminary injunction granted	Court weighed patent validity and potential irreparable harm.
December 2014	Patent invalidity defenses raised	Accord challenged the patents’ novelty, obviousness, and enablement.
June 2015	Summary judgment motions filed	Both parties moved for partial or full judgments.
November 2015	Trial held	Court analyzed whether patents were infringed and valid.
June 2016	Court decision issued	Patent infringement found; some claims invalidated.
December 2016	Appeals filed	Both parties appealed substantive legal findings.

---

What Were the Key Judicial Findings?

Patent Validity and Invalidity Determinations

• Validity: The court upheld the validity of specific claims relating to the formulation’s novelty but invalidated some claims on grounds of obviousness.
• Infringement: Accord's generic design was found to infringe the remaining valid patent claims, leading to an injunction against sales of the infringing product.

Court's Rationale

• The court relied on prior art, including earlier formulations and manufacturing techniques, to assess obviousness.
• Patent claims emphasizing a particular crystalline form were upheld after examining the structural differences and process patents.
• Claims deemed overly broad or missing sufficient inventive step were invalidated under 35 U.S.C. § 103.

---

Damages and Injunctive Relief

• The court granted Cephalon injunctive relief against Accord, halting further sales of the infringing generic.
• Cephalon awarded monetary damages for past infringement, with exact figures depending on sales data and patent terms.

---

What Were the Patent and Litigation Implications?

Implications	Details
Patent Strategy	Highlighted importance of asserting multiple patent types (composition, method, process).
Patent Validity Challenges	Demonstrates necessity of robust patent prosecution, especially against obviousness.
Generics’ Design-Arounds	Allowed assessing how minor modifications impact infringement and validity.
Regulatory and Litigation Interplay	Emphasized necessity of aligning patent strategy with FDA approval pathways (ANDA submissions).
Patent Term and Exclusivity	Reinforced that patents extending exclusivity rely on defensible claims, especially in complex biologic-like drugs.

---

Comparison with Industry Practices

Aspect	Cephalon v. Accord	Typical Industry Practice
Patent Scope	Narrowed on crystalline forms	Broad claims on formulations and methods
Patent Defense	Validity challenged on obviousness	Often defend validity robustly
Litigation Outcome	Infringement upheld, some claims invalidated	Commonly involves disputes over claim scope and validity
Injunctions	Granted selectively	Courts tend to balance sales harm with patent strength

---

Deep Dive: What Are the Lessons for Patent Filings and Litigation?

• Draft comprehensive patent claims covering multiple aspects—material composition, manufacturing process, and method of use.
• Anticipate obviousness challenges by providing detailed experimental data and novel technical features.
• Monitor prior art continuously to identify gaps and strengthen patent claims preemptively.
• Align patent strategy with FDA process to defend exclusivity during ANDA approvals.
• Prepare for litigation by documenting invention conception and development thoroughly.

---

Frequently Asked Questions

Q1: How does this case impact future patent filings for complex drugs?

A: It underscores the importance of drafting narrower, robust claims that withstand obviousness challenges, especially when prior art is extensive. Including detailed specifications and multiple claim types provides stronger legal footing.

Q2: What does this case indicate about the enforceability of crystalline form patents?

A: Crystalline form patents can be enforceable if claims are specific and supported by structural analysis, but generic manufacturers can design around such claims by modifying crystalline forms.

Q3: How do patent invalidity defenses, like obviousness, typically impact patent litigation?

A: They are frequently successful, especially when prior art suggests similar formulations or manufacturing methods. Such defenses often lead to invalidation of broad or overly obvious claims.

Q4: What role does the FDA play in patent litigation for generic drugs?

A: The FDA’s approval process via ANDA filings is central, as patent disputes often precede or coincide with regulatory approvals. Patent litigation can delay generic entry, impacting market exclusivity.

Q5: How can brand companies defend against generic patent challenges effectively?

A: By securing defensible, specific patents, conducting thorough prior art searches, and preparing patent claims with clear inventive steps, along with proactive litigation strategies.

---

Key Takeaways

• Patent robustness is critical: Broad, well-supported claims sustain enforcement and defend against invalidity challenges.
• Obviousness remains a key battleground: Prior art and inventive step arguments can invalidate patents, as seen in this case.
• Early preparation matters: Strategic patent filings aligned with FDA pathways can extend exclusivity.
• Design-around strategies influence infringement outcomes significantly.
• Case law reinforces the importance of precise claim language and comprehensive patent prosecution.

---

References

[1] Cephalon Inc. v. Accord Healthcare Inc., 1:13-cv-02095, U.S. District Court, District of Delaware, 2016.
[2] Federal Circuit Court of Appeals decision, 2017.
[3] FDA ANDA Regulations (21 CFR Part 314).
[4] Patent Law Principles – 35 U.S.C. § 103 (Obviousness).
[5] Industry analyses on patent strategies in pharmaceuticals, Nature Reviews Drug Discovery, 2018.